Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.

CONCLUSIONS: Collectively, our data demonstrate that PP2A inhibition radiosensitizes pancreatic cancer both in vitro and in vivo via activation of CDC25C/CDK1 and inhibition of HRR, and provide proof-of-concept evidence that PP2A is a promising target for the improvement of local therapy in pancreatic cancer.
PMID: 23780887 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - June 18, 2013 Category: Cancer & Oncology Authors: Wei D, Parsels L, Karnak D, Davis M, Parsels J, Zhao LL, Maybaum J, Lawrence T, Sun Y, Morgan MA Tags: Clin Cancer Res Source Type: research